<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04337437</url>
  </required_header>
  <id_info>
    <org_study_id>GenSci 048-I CT</org_study_id>
    <nct_id>NCT04337437</nct_id>
  </id_info>
  <brief_title>Clinical Study of Genakumab for Injection in Chinese Healthy Volunteers</brief_title>
  <official_title>The Phase I Clinical Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Genakumab for Injection in Chinese Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GeneScience Pharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>GeneScience Pharmaceuticals Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and tolerability of single subcutaneous injection of Genakumab for
      Injection in Chinese healthy adult volunteers
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are 5 dose groups with 8 participants in each group, including 6 participants in the
      experimental group and 2 participants in the placebo control group.

      Since the strength of experimental drug is 150mg/1ml/ bottle, participants with a single dose
      of more than 150mg need to be given subcutaneously at different sites in two or more times
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 22, 2019</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double-blind (participant, investigator), excluding one non-blind investigator doctor.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed serum Genakumab concentration</measure>
    <time_frame>Baseline, 0.5h, 1h, 2h, 4h, 8h, 12h, 24h, 48h, 72h, 96h, 168h, Day 15, Day 22, Day 29, Day 43, Day 57, Day 71, Day 85, Day 99, Day 113 after administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the serum Genakumab concentration-time curve</measure>
    <time_frame>Baseline, 0.5h, 1h, 2h, 4h, 8h, 12h, 24h, 48h, 72h, 96h, 168h, Day 15, Day 22, Day 29, Day 43, Day 57, Day 71, Day 85, Day 99, Day 113 after administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of the serum IL-1β for pharmacodynamics study</measure>
    <time_frame>Baseline, 0.5h, 1h, 2h, 4h, 8h, 12h, 24h, 48h, 72h, 96h, 168h, Day 15, Day 22, Day 29, Day 43, Day 57, Day 71, Day 85, Day 99, Day 113 after administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The frequency of adverse events (AE)</measure>
    <time_frame>From screening to follow-up period (up to day 22)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Juvenile Idiopathic Arthritis</condition>
  <arm_group>
    <arm_group_label>Genakumab injection：5 groups</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 mg/1ml/bottle, single subcutaneous injection. Group A : 0.3mg/kg, Group B : 1mg/kg, Group C : 2mg/kg, Group D：4mg/kg, Group E : 6mg/kg,</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for this trial : 5 groups</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo contains other excipients except Genakumab, and its appearance is consistent with that of Genakumab for injection, 150 mg/1ml/bottle, single subcutaneous injection.
Group A : 0.3mg/kg, Group B : 1mg/kg, Group C : 2mg/kg, Group D：4mg/kg, Group E : 6mg/kg,</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Genakumab</intervention_name>
    <description>150 mg/1ml/bottle, single subcutaneous injection.</description>
    <arm_group_label>Genakumab injection：5 groups</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for this trial</intervention_name>
    <description>The placebo contains other excipients except Genakumab, and its appearance is consistent with that of Genakumab for injection, 150 mg/1ml/bottle, single subcutaneous injection.</description>
    <arm_group_label>Placebo for this trial : 5 groups</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years ≤ age ≤50 years, and in good health;

          -  40kg ≤ weight ≤100kg , and body mass index is within the range of 18 - 28 kg/m^2
             (including 18 kg/m^2 and 28 kg/m^2);

          -  No parental scheme from the screening period to 6 months after the study period.

        Exclusion Criteria:

          -  Participants have abnormal physical and auxiliary examination results with clinical
             significance;

          -  History of cardiovascular, liver, kidney, digestive, blood, nervous system and
             allergic diseases, mental and metabolic disorders, acute or chronic bronchospastic
             disease;

          -  Smoking more than 5 cigarettes per day;

          -  Participants who use any prescription drugs within 4 weeks prior dosing, or
             over-the-counter medication within 2 weeks prior to dosing. Participants who receive
             treatment of any biologics within three months prior to dosing. Participants who
             receive (attenuated) live vaccines within six months prior to dosing;

          -  Participation in any clinical investigation within 3 months prior to dosing;

          -  Donation or loss of 400 mL or more of blood within 3 months prior to dosing; donation
             or loss of 200 mL or more of blood within 4 weeks prior to dosing; or donation of
             component blood within 2 weeks prior to dosing;

          -  Tuberculosis symptoms, contact with patients with suspected tuberculosis symptoms

          -  Positive results in Hepatitis B surface antigen (HBsAg), Hepatitis C antibody,
             Syphilis antibody or HIV antibody;

          -  Clinically significant acute infection within 2 weeks prior to dosing;

          -  Current or previous drug or alcohol abuse;

          -  Other conditions in which the investigator preclude enrollment into the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rui Chen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Pharmacology Research Center of Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luocheng Xu</last_name>
    <phone>800-820-0469</phone>
    <email>xuluocheng@gensci-china.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Pharmacology Research Center of Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rui Chen</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>April 1, 2020</study_first_submitted>
  <study_first_submitted_qc>April 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 7, 2020</study_first_posted>
  <last_update_submitted>April 3, 2020</last_update_submitted>
  <last_update_submitted_qc>April 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis, Juvenile</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

